What it's for (Indications)
- The varicella virus vaccine (live attenuated, 0.
- 5ml), exemplified by brands like Varilrix, is indicated for active immunization against varicella (chickenpox) disease in susceptible individuals.
- It is primarily recommended for routine immunization of healthy children starting at 12 months of age, adolescents, and adults who have not previously had chickenpox or been vaccinated.
- Vaccination aims to prevent primary varicella infection and its associated complications, including severe skin lesions, pneumonia, encephalitis, and Reye's syndrome.
- Immunization is also crucial for preventing outbreaks in institutional settings and protecting vulnerable individuals through herd immunity.
- Catch-up vaccination is advised for children and adolescents who missed their primary doses.
- Specific populations, such as healthcare workers, teachers, caregivers of immunocompromised individuals, and non-pregnant women of childbearing age, who are seronegative for varicella, are also strong candidates for vaccination to reduce their risk of infection and transmission.
- The vaccine's efficacy in preventing moderate to severe varicella is high, significantly reducing disease burden.
- This vaccine provides a critical public health intervention, substantially decreasing the incidence and severity of varicella-related morbidity and mortality across diverse age groups.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For individuals 12 months of age and older, the recommended dosage for the varicella virus vaccine (0.5ml) is administered as two separate doses. The first dose is typically given at 12 to 15 months of age. The second dose is usually administered at 4 to 6 years of age, or at least 3 months after the first dose, particularly in situations where accelerated schedules are required. For adolescents (13 years of age and older) and adults who have not been vaccinated and have no evidence of immunity, the standard vaccination schedule involves two doses administered 4 to 8 weeks apart, or as per national immunization guidelines, to ensure optimal seroconversion and protection. Each dose consists of 0.5ml of the reconstituted vaccine solution, administered via subcutaneous injection, preferably into the deltoid region of the upper arm. It is crucial to adhere strictly to the recommended dosing schedule and intervals to achieve maximum vaccine effectiveness and long-lasting immunity against varicella. Any deviation from the recommended schedule should be discussed with a healthcare professional to ensure appropriate catch-up vaccination strategies are implemented. |
Safety & Warnings
Common Side Effects
- Common side effects associated with the varicella virus vaccine (0.
- 5ml) are generally mild and transient, primarily involving local reactions at the injection site.
- These may include pain, tenderness, redness (erythema), swelling, and a rash resembling varicella lesions (maculopapular or vesicular) at the site of injection.
- Systemic reactions can also occur and typically manifest as fever (usually low-grade), irritability, fatigue, and headache.
- Less commonly, individuals may experience a generalized varicella-like rash, which is usually mild, consisting of a few lesions, and can occur anywhere on the body.
- Other infrequent but reported adverse events include upper respiratory tract infection, cough, nausea, vomiting, diarrhea, myalgia, and arthralgia.
- Serious adverse reactions are rare but can include anaphylaxis or severe allergic reactions, requiring immediate medical intervention.
- Neurological events, such as febrile seizures, ataxia, and encephalitis, have been reported but are exceedingly rare, and a causal link is often difficult to establish definitively.
- Aseptic meningitis and transient thrombocytopenia have also been observed on rare occasions.
- Any concerning or severe reaction post-vaccination should be promptly reported to a healthcare provider.
- The benefits of vaccination in preventing varicella disease and its complications far outweigh the risks of these generally mild side effects.
Serious Warnings
- Black Box Warning: A formal FDA Black Box Warning, as typically formatted for pharmaceutical drugs with severe, life-threatening risks, does not apply to the varicella virus vaccine (0.5ml), such as Varilrix. However, due to the live attenuated nature of the vaccine, critical 'Serious Warnings' must be considered and communicated to patients and healthcare providers. These warnings highlight significant risks for specific vulnerable populations. Severe immunosuppression, whether due to disease (e.g., leukemia, lymphoma, severe HIV infection, severe combined immunodeficiency) or immunosuppressive therapy (e.g., high-dose corticosteroids, chemotherapy), constitutes an absolute contraindication due to the risk of uncontrolled vaccine virus replication, potentially leading to disseminated vaccine-associated disease, which can be life-threatening. Similarly, pregnancy is a strict contraindication, and women of childbearing potential must be advised to avoid pregnancy for at least one month post-vaccination due to the theoretical risk of congenital malformations from the live attenuated virus. Healthcare providers must perform a thorough medical history and screening for all patients to identify these high-risk factors before administration. While very rare, severe allergic reactions, including anaphylaxis, can occur; therefore, appropriate medical treatment and supervision must be readily available during and immediately following vaccination. Although vaccine virus transmission is exceedingly rare, individuals who develop a post-vaccination rash should avoid close contact with highly susceptible individuals, such as severe immunocompromised persons and pregnant women who are not immune to varicella, to prevent potential transmission.
- Healthcare professionals should exercise caution when administering the varicella virus vaccine to individuals with a history of seizures, particularly those with a personal or family history of febrile seizures, as fever may occur post-vaccination and trigger such events.
- Syncope (fainting) can occur following or even before any vaccination, primarily due to psychogenic response to the injection; procedures should be in place to prevent injury from fainting.
- While extremely rare, transmission of the vaccine virus from vaccinated individuals who develop a varicella-like rash to susceptible contacts (e.
- g.
- , immunocompromised individuals, pregnant women who have not had varicella) has been documented; therefore, vaccine recipients should avoid close contact with such high-risk individuals for several weeks following vaccination if a rash develops.
- Immunosuppressed individuals, even if they do not meet contraindication criteria, may have a diminished immune response to the vaccine; careful risk-benefit assessment is required.
- Administration of immunoglobulins or blood products containing antibodies should be avoided shortly before or after vaccination, as they can interfere with the immune response to the vaccine.
- Patients should be advised about the potential for transient rash and the importance of reporting any severe or unusual symptoms.
- Proper storage and reconstitution of the vaccine are critical to maintain its potency.
- It is essential to ensure that the patient is not acutely ill with a moderate to severe febrile illness before vaccination, although minor infections without fever typically do not contraindicate vaccination.
- Comprehensive pre-vaccination screening is crucial to identify any potential warnings or contraindications.
How it Works (Mechanism of Action)
The varicella virus vaccine (0.5ml) operates through the principle of active immunization using a live, attenuated strain of the varicella-zoster virus (VZV), specifically the Oka/Merck strain for many formulations, including Varilrix. Upon subcutaneous injection, the attenuated virus replicates in the host, albeit at a reduced and controlled rate compared to the wild-type virus, without causing overt disease in most individuals. This controlled replication stimulates a primary immune response, mimicking a natural infection without the associated risks. The host's immune system recognizes the viral antigens presented by the attenuated virus, leading to the activation of both humoral and cell-mediated immunity. Specifically, B lymphocytes are activated to produce VZV-specific antibodies (e.g., IgG, IgM), which play a crucial role in neutralizing circulating virus. Concurrently, T lymphocytes, including cytotoxic T cells, are activated to identify and destroy VZV-infected cells. This robust immune response generates immunological memory, meaning the body is primed to rapidly recognize and neutralize the wild-type VZV upon subsequent exposure, thereby preventing or significantly attenuating varicella disease. The attenuated virus strain has undergone modifications to reduce its virulence while retaining its immunogenicity, providing effective protection against chickenpox by establishing long-term immunity.